Equities

Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.21
  • Today's Change-0.04 / -3.20%
  • Shares traded177.98k
  • 1 Year change+71.15%
  • Beta1.4597
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.

  • Revenue in USD (TTM)18.16m
  • Net income in USD-12.42m
  • Incorporated2012
  • Employees70.00
  • Location
    Ekso Bionics Holdings Inc101 GLACIER POINT, SUITE ASAN RAFAEL 94901United StatesUSA
  • Phone+1 (510) 984-1761
  • Fax+1 (702) 866-2689
  • Websitehttps://ir.eksobionics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inspira Technologies Oxy BHN Ltd0.00-11.29m23.23m37.00--3.44-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Femasys Inc950.09k-16.69m26.01m32.00--2.31--27.38-0.8468-0.84680.04720.50600.05490.34387.6529,690.31-96.51---108.58--65.67---1,756.83--5.93-77.250.2972---11.13---25.04------
Meihua International Medical Tech Co Ltd97.10m11.63m26.22m617.002.120.16852.170.2700.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Retractable Technologies Inc38.25m-18.10m26.91m148.00--0.3158--0.7035-0.6046-0.60461.282.850.22021.446.42258,468.00-10.2812.45-10.7914.5119.1940.82-46.7118.096.54-2.860.016---54.025.55-249.46--17.42--
Ekso Bionics Holdings Inc18.16m-12.42m26.99m70.00--1.91--1.49-0.7909-0.79091.130.65380.59571.653.14259,428.60-40.75-43.63-57.60-57.6751.8351.93-68.41-104.241.77-23.990.3172--41.5710.03-0.7825--3.69--
bioAffinity Technologies Inc7.32m-8.74m27.12m75.00--6.73--3.71-0.9007-0.90070.74390.29890.9422236.818.6897,545.07-112.51---140.58--35.47---119.41--1.14-296.510.234--52,660.42--2.66------
Positron Corp1.24m-1.27m27.23m22.00------22.01-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
Golden Valley Development Inc0.00-92.53k27.36m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Neuronetics Inc72.07m-32.47m28.70m203.00--1.47--0.3983-1.10-1.102.450.64330.73092.314.76355,000.00-32.93-28.02-42.47-34.7375.9175.73-45.06-51.042.37-3.920.755--9.426.2218.76--18.57--
Neuroone Medical Technologies Corp3.96m-12.10m28.81m16.00--8.65--7.27-0.4916-0.49160.15930.10820.74281.6919.31247,702.50-226.84-172.88-334.70-274.7429.60---305.37-674.971.36--0.00--62.66---18.60------
Know Labs Inc0.00-16.34m29.68m15.00---------0.2204-0.22040.00-0.05330.00----0.00-442.53-209.16---1,087.76-------1,302.62---15.986.21---100.00---1.85---3.64--
DarioHealth Corp19.15m-46.52m30.03m223.00--0.4411--1.57-1.51-1.510.58032.270.162.393.3169,373.19-42.46-73.26-47.52-87.5930.9729.54-265.33-293.541.96--0.2961---26.4122.450.5091--52.42--
Data as of Sep 20 2024. Currency figures normalised to Ekso Bionics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

16.98%Per cent of shares held by top holders
HolderShares% Held
Kent Lake Capital LLCas of 30 Aug 20241.67m9.05%
The Vanguard Group, Inc.as of 30 Jun 2024594.43k3.22%
Cresset Asset Management LLCas of 30 Jun 2024300.00k1.63%
Azimut Capital Management SGR SpAas of 31 Jul 2024209.12k1.13%
Geode Capital Management LLCas of 30 Jun 2024135.82k0.74%
Renaissance Technologies LLCas of 30 Jun 202475.52k0.41%
BlackRock Fund Advisorsas of 30 Jun 202454.75k0.30%
IMPact SGR SpAas of 28 Mar 202443.00k0.23%
Banque Lombard Odier & Cie SA (Investment Management)as of 30 Jun 202425.00k0.14%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202424.85k0.14%
More ▼
Data from 28 Mar 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.